## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Friddle et al.

Application No.:

10/054,680

01/22/02

Group Art Unit: 1641

Title:

Novel Human Ion Exchanger Proteins and Examiner:

To Be Assigned

Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0301-USA

Commissioner for Patents Washington, D.C. 20231 Box DD

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

<u>X</u>	(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
_	under 37 CFR 1.97(c) together with either a:  Certification under 37 CFR 1.97(e), or  a \$240.00 fee under 37 CFR 1.17(p), or  (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
	under 37 CFR 1.97(d) together with a:  Certification under 37 CFR 1.97(e), and a petition under 37 CFR 1.97(d)(2)(ii), and a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).  (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

May 10, 2002

Date

Lance K Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED (281) 863-3333

24231